Novartis AG ROE 2006-2018 | NVS

Current and historical return on equity (ROE) values for Novartis AG (NVS) over the last 10 years.
Novartis AG Annual ROE - Return on Equity
2017 10.38
2016 8.94
2015 9.11
2014 15.14
2013 12.50
2012 13.76
2011 13.76
2010 14.29
2009 14.71
2008 16.19
2007 13.24
2006 16.53
2005 17.73
Novartis AG Quarterly ROE - Return on Equity
Q2 2018 10.10
Q1 2018 2.85
Q4 2017 2.66
Q3 2017 0.00
Q2 2017 0.00
Q1 2017 0.00
Q4 2016 1.25
Q3 2016 2.59
Q2 2016 2.49
Q1 2016 2.80
Q4 2015 1.37
Q3 2015 2.36
Q2 2015 2.35
Q1 2015 3.02
Q4 2014 3.46
Q3 2014 0.00
Q2 2014 0.00
Q1 2014 0.00
Q4 2013 2.88
Q3 2013 0.00
Q2 2013 0.00
Q1 2013 0.00
Q4 2012 3.13
Q3 2012 3.60
Q2 2012 4.16
Q1 2012 3.59
Q4 2011 1.57
Q3 2011 0.00
Q2 2011 0.00
Q1 2011 0.00
Q4 2010 3.25
Q3 2010 0.00
Q2 2010 0.00
Q1 2010 0.00
Q4 2009 4.04
Q3 2009 0.00
Q2 2009 0.00
Q1 2009 0.00
Q4 2008 2.99
Q3 2008 0.00
Q2 2008 0.00
Q1 2008 0.00
Q4 2007 1.89
Q3 2007 0.00
Q2 2007 0.00
Q1 2007 0.00
Q4 2006 3.73
Q3 2006 0.00
Q2 2006 0.00
Q1 2006 0.00
Q4 2005 3.29
Q3 2005 0.00
Q2 2005 0.00
Q1 2005 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.442B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Merck (MRK) United States $186.199B 16.44
AbbVie (ABBV) United States $149.625B 14.62
Novo Nordisk (NVO) Denmark $115.970B 18.54
Eli Lilly (LLY) United States $113.359B 20.98
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62